000126391 001__ 126391
000126391 005__ 20240228135024.0
000126391 0247_ $$2doi$$a10.1002/pbc.25002
000126391 0247_ $$2pmid$$apmid:24616042
000126391 0247_ $$2ISSN$$a0098-1532
000126391 0247_ $$2ISSN$$a1096-911X
000126391 0247_ $$2ISSN$$a1545-5009
000126391 0247_ $$2ISSN$$a1545-5017
000126391 0247_ $$2altmetric$$aaltmetric:2144921
000126391 037__ $$aDKFZ-2017-02420
000126391 041__ $$aeng
000126391 082__ $$a610
000126391 1001_ $$aRamaswamy, Vijay$$b0
000126391 245__ $$aDuration of the pre-diagnostic interval in medulloblastoma is subgroup dependent.
000126391 260__ $$aNew York, NY$$bWiley$$c2014
000126391 3367_ $$2DRIVER$$aarticle
000126391 3367_ $$2DataCite$$aOutput Types/Journal article
000126391 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1505481059_23151
000126391 3367_ $$2BibTeX$$aARTICLE
000126391 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000126391 3367_ $$00$$2EndNote$$aJournal Article
000126391 520__ $$aChildren presenting with medulloblastoma have a wide range of initial presenting symptoms. However, the influence of underlying tumor biology on the initial presentation of medulloblastoma is currently unknown. In light of the recent discovery of distinct medulloblastoma subgroups, we sought to define the initial presentation of childhood medulloblastoma in a subgroup specific manner.We assembled a cohort of 126 medulloblastoma cases at the Hospital for Sick Children between 1994 and 2012 and determined subgroup affiliation using nanoString. Clinical details pertaining to the initial presentation were determined through a retrospective chart review.The median pre-diagnostic interval across all medulloblastoma cases was 4 weeks (IQR: 4-12 weeks). Strikingly, when the pre-diagnostic interval was then determined in a subgroup specific manner, cases with WNT and Group 4 tumors showed significantly longer median pre-diagnostic intervals of 8 weeks compared to 2 weeks for SHH and 4 weeks for Group 3 (P = 0.0001). Younger age was significantly associated with a prolonged pre-diagnostic interval (P = 0.02 for all). When stratifying by subgroup the association with age was only significant in Group 4 (P = 0.04 for Group 4). Improved survival was significantly associated with a longer pre-diagnostic interval (P = 0.02), however is no longer significant when controlling for subgroup (P = 0.07).The duration of the pre-diagnostic interval in childhood medulloblastoma is highly subgroup dependent, further highlighting the clinical heterogeneity and biological relevance of the four principle subgroups of medulloblastoma.
000126391 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000126391 588__ $$aDataset connected to CrossRef, PubMed,
000126391 7001_ $$0P:(DE-HGF)0$$aRemke, Marc$$b1
000126391 7001_ $$aShih, David$$b2
000126391 7001_ $$aWang, Xin$$b3
000126391 7001_ $$0P:(DE-HGF)0$$aNorthcott, Paul A$$b4
000126391 7001_ $$aFaria, Claudia C$$b5
000126391 7001_ $$aRaybaud, Charles$$b6
000126391 7001_ $$aTabori, Uri$$b7
000126391 7001_ $$aHawkins, Cynthia$$b8
000126391 7001_ $$aRutka, James$$b9
000126391 7001_ $$aTaylor, Michael D$$b10
000126391 7001_ $$aBouffet, Eric$$b11
000126391 773__ $$0PERI:(DE-600)2130978-4$$a10.1002/pbc.25002$$gVol. 61, no. 7, p. 1190 - 1194$$n7$$p1190 - 1194$$tPediatric blood & cancer$$v61$$x1545-5009$$y2014
000126391 909CO $$ooai:inrepo02.dkfz.de:126391$$pVDB
000126391 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000126391 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000126391 9141_ $$y2014
000126391 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000126391 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000126391 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000126391 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPEDIATR BLOOD CANCER : 2015
000126391 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000126391 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000126391 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000126391 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000126391 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000126391 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000126391 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000126391 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000126391 980__ $$ajournal
000126391 980__ $$aVDB
000126391 980__ $$aI:(DE-He78)B062-20160331
000126391 980__ $$aUNRESTRICTED